Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Aberrantly expressed circulating microRNAs (miRNAs) have been demonstrated to have a crucial role in the diagnosis and prognostication of various cancers, including hepatocellular carcinoma (HCC). This research aimed to examine the role of specific miRNAs in predicting the outcomes for individuals with hepatitis B virus (HBV)-related HCC treated with transarterial chemoembolization (TACE). Stored serum specimens collected prior to the first TACE procedure were employed to determine the expression of serum miR-122, miR-221, and miR-224 using quantitative real-time PCR analysis. The study included 100 HCC patients (84% males, with an average age of 60 years) who were treated with TACE. Throughout the median follow-up spanning 18.5 months (within a range of 3 to 60 months), 42 (42.0%) patients met the criteria of TACE refractoriness. Through multivariate analysis, elevated expressed miR-221 (≥4.0 log10 copies) and advanced HCC staging were identified as independent factors related to TACE refractoriness and short overall survival. However, serum miR-122 and miR-224 levels were not linked to treatment response or overall survival. These findings underscored the potential of incorporating pretreatment levels of serum miR-221 into the established tumor staging to enhance the accurate assessment of TACE responsiveness and prognostic outcome of patients with HCC.

[1]  R. A. Abo El-Wafa,et al.  Circulating MiRNA-373 as a Predictor of Response to Super-Selective Transarterial Chemoembolization Bridging Therapy in Hepatocellular Carcinoma Patients Awaiting Liver Transplantation , 2023, Asian Pacific journal of cancer prevention : APJCP.

[2]  B. Rah,et al.  Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma , 2022, Frontiers in Genetics.

[3]  T. Aboushousha,et al.  MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma , 2022, Non-coding RNA research.

[4]  A. Bozzato,et al.  MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View , 2022, Diagnostics.

[5]  Xiaolin Wang,et al.  MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases , 2020, Gut.

[6]  C. Winkler,et al.  Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets , 2020, Frontiers in Oncology.

[7]  Jun Kato,et al.  Switching to systemic therapy after locoregional treatment failure: Definition and best timing , 2020, Clinical and molecular hepatology.

[8]  Lining Wang,et al.  Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects , 2019, BMC Cancer.

[9]  H. Keyvani,et al.  microRNAs: Key players in virus‐associated hepatocellular carcinoma , 2018, Journal of cellular physiology.

[10]  I. Ng,et al.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications , 2018, Nature Reviews Gastroenterology & Hepatology.

[11]  K. Lee,et al.  Plasma micoRNA‐122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma , 2017, Journal of gastroenterology and hepatology.

[12]  D. Ichikawa,et al.  Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function , 2016, Oncotarget.

[13]  Xiao-feng He,et al.  Serum microRNA-199a/b-3p as a predictive biomarker for treatment response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization , 2016, OncoTargets and therapy.

[14]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[15]  S. Ahn,et al.  Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic score , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[16]  B. Bai,et al.  Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma , 2015, Cellular Physiology and Biochemistry.

[17]  F. Hucke,et al.  Transarterial chemoembolization: modalities, indication, and patient selection. , 2015, Journal of hepatology.

[18]  S. Pfeffer,et al.  miR-122--a key factor and therapeutic target in liver disease. , 2015, Journal of hepatology.

[19]  M. Kudo,et al.  Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update , 2014, Oncology.

[20]  Changchun Zhou,et al.  Association of Serum MicroRNA Expression in Hepatocellular Carcinomas Treated with Transarterial Chemoembolization and Patient Survival , 2014, PloS one.

[21]  Ligong Lu,et al.  Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. , 2014, Journal of vascular and interventional radiology : JVIR.

[22]  H-S Liu,et al.  Autophagy Suppresses Tumorigenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma Through Degradation of MicroRNA-224 , 2013, Hepatology.

[23]  Stefan L Ameres,et al.  Diversifying microRNA sequence and function , 2013, Nature Reviews Molecular Cell Biology.

[24]  S. Pfeffer,et al.  miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. , 2013, Journal of hepatology.

[25]  Y. Dang,et al.  Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro , 2013, BMC Cancer.

[26]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[27]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[28]  Zheng Wang,et al.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Thomas D. Schmittgen,et al.  miR-221 silencing blocks hepatocellular carcinoma and promotes survival. , 2011, Cancer research.

[30]  Peng Gao,et al.  Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. , 2011, Journal of hepatology.

[31]  Wanjun Yu,et al.  Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. , 2011, Biochemical and biophysical research communications.

[32]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[33]  W. Tan,et al.  Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis , 2011, Molecular Carcinogenesis.

[34]  X. Chen,et al.  Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. , 2010, Cancer research.

[35]  B. Cullen,et al.  Viruses, microRNAs, and host interactions. , 2010, Annual review of microbiology.

[36]  Zhimin Zhang,et al.  MicroRNA‐224 is upregulated in HepG2 cells and involved in cellular migration and invasion , 2010, Journal of gastroenterology and hepatology.

[37]  S. Lowe,et al.  miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[38]  Gian Luca Grazi,et al.  MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality , 2009, Clinical Cancer Research.

[39]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[40]  Shune Yang,et al.  Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma. , 2017, Cancer biomarkers : section A of Disease markers.